DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hdrfv6/collaborative) has announced the addition of the "Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics" report to their offering.
The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in collaborative R&D dealmaking
Chapter 3 - Overview of collaborative R&D deal structure
Chapter 4 - Leading collaborative R&D deals
Chapter 5 - Collaborative R&D deal term benchmarks
Chapter 6 - Bigpharma collaborative R&D deals
Chapter 7 - Bigbiotech collaborative R&D deals
Chapter 8 - Collaborative R&D contract directory 2009-2014
For more information visit http://www.researchandmarkets.com/research/hdrfv6/collaborative